Inmagene Biopharmaceuticals Exercises Option to License HUTCHMED’s IMG-007 and IMG-004
Shots:
- HUTCHMED’s IMG-007 and IMG-004 are licensed by Inmagene as “options to license” under the terms of the agreement signed in Jan 2021. Inmagene will further develop, manufacture and commercialize the drugs
- As per the terms, HUTCHMED, for each of its drugs, will obtain ~$92.5M milestones for their development and ~$135M on achieving commercial milestones plus royalties associated with commercialization
- Additionally, Inmagene has commenced two P-IIa studies evaluating IMG-007 for treating adults with moderate-to-severe atopic dermatitis and alopecia areata. It also concluded P-I single ascending dose (SAD) trial for immunological diseases
Ref: HUTCHMED | Image: Inmagene
Related News:- Chi-Med and Inmagene Collaborate to Develop Therapies for Immunological Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
